CNSL Stock Overview
Develops, manufactures, and distributes medical diagnostics products for the food sensitivity testing market in the United Kingdom, rest of Europe, North America, South/Central America, India, rest of Asia and the Far East, Africa, and the Middle East. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Cambridge Nutritional Sciences plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.029 |
| 52 Week High | UK£0.045 |
| 52 Week Low | UK£0.023 |
| Beta | 3.91 |
| 1 Month Change | -19.72% |
| 3 Month Change | -17.39% |
| 1 Year Change | 11.76% |
| 3 Year Change | -88.25% |
| 5 Year Change | -80.21% |
| Change since IPO | -91.86% |
Recent News & Updates
Investors Don't See Light At End Of Cambridge Nutritional Sciences plc's (LON:CNSL) Tunnel
Nov 19
The Market Doesn't Like What It Sees From Cambridge Nutritional Sciences plc's (LON:CNSL) Revenues Yet
Jul 27Recent updates
Investors Don't See Light At End Of Cambridge Nutritional Sciences plc's (LON:CNSL) Tunnel
Nov 19The Market Doesn't Like What It Sees From Cambridge Nutritional Sciences plc's (LON:CNSL) Revenues Yet
Jul 27Cambridge Nutritional Sciences plc's (LON:CNSL) Shares Lagging The Industry But So Is The Business
Mar 14We Think Omega Diagnostics Group (LON:ODX) Needs To Drive Business Growth Carefully
Nov 06This Is Why Omega Diagnostics Group PLC's (LON:ODX) CEO Compensation Looks Appropriate
Sep 09Companies Like Omega Diagnostics Group (LON:ODX) Are In A Position To Invest In Growth
Jun 14How Does Omega Diagnostics Group's (LON:ODX) CEO Salary Compare to Peers?
Mar 01Announcing: Omega Diagnostics Group (LON:ODX) Stock Soared An Exciting 301% In The Last Year
Feb 01
What You Need To Know About Omega Diagnostics Group PLC's (LON:ODX) Investor Composition
Jan 04We're Hopeful That Omega Diagnostics Group (LON:ODX) Will Use Its Cash Wisely
Dec 09Shareholder Returns
| CNSL | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | -1.7% | -2.0% | -1.4% |
| 1Y | 11.8% | -7.9% | 4.6% |
Return vs Industry: CNSL exceeded the UK Medical Equipment industry which returned -7.9% over the past year.
Return vs Market: CNSL exceeded the UK Market which returned 4.6% over the past year.
Price Volatility
| CNSL volatility | |
|---|---|
| CNSL Average Weekly Movement | 5.5% |
| Medical Equipment Industry Average Movement | 6.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: CNSL has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: CNSL's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 94 | James Cooper | www.cnsplc.com |
Cambridge Nutritional Sciences plc, together with its subsidiaries, develops, manufactures, and distributes medical diagnostics products for the food sensitivity testing market in the United Kingdom, rest of Europe, North America, South/Central America, India, rest of Asia and the Far East, Africa, and the Middle East. The company is involved in the research, development, and production of kits for detection of immune reactions to food under the FoodPrint brand. It also provides clinical analysis to the general public, clinics, and health professionals; and supplies Food Detective, a food sensitivity test.
Cambridge Nutritional Sciences plc Fundamentals Summary
| CNSL fundamental statistics | |
|---|---|
| Market cap | UK£6.78m |
| Earnings (TTM) | UK£174.00k |
| Revenue (TTM) | UK£8.97m |
39.0x
P/E Ratio0.8x
P/S RatioIs CNSL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CNSL income statement (TTM) | |
|---|---|
| Revenue | UK£8.97m |
| Cost of Revenue | UK£3.32m |
| Gross Profit | UK£5.66m |
| Other Expenses | UK£5.48m |
| Earnings | UK£174.00k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.00073 |
| Gross Margin | 63.02% |
| Net Profit Margin | 1.94% |
| Debt/Equity Ratio | 0% |
How did CNSL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 03:47 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cambridge Nutritional Sciences plc is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Adam McCarter | Cavendish |
| Ian Berry | Cavendish Historical (Cenkos Securities) |
| John Savin | Edison Investment Research |